16-Methoxyhexadecanal | 288851-55-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 16-Methoxyhexadecanal
• CAS: 288851-55-8
• 化学式: C₁₇H₃₄O₂
• 分子量: 270.456
• InChiKey: RDERSISJFAYEQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  19
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [5-Oxo-2-(phenylmethoxymethyl)oxolan-2-yl]methyl 2,2-dimethylpropanoate 、 16-Methoxyhexadecanal 在 lithium hexamethyldisilazane 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (E)-(2-(hydroxymethyl)-4-(16-methoxyhexadecylidene)-5-oxotetrahydrofuran-2-yl)methyl pivalate 、 (Z)-(2-(hydroxymethyl)-4-(16-methoxyhexadecylidene)-5-oxotetrahydrofuran-2-yl)methyl pivalate
  参考文献：
  名称：

  Polar 3-alkylidene-5-pivaloyloxymethyl-5′-hydroxymethyl-γ-lactones as protein kinase C ligands and antitumor agents

  摘要：

  A series of DAG-lactones with polar 3-alkylidene substituents have been investigated as PKC-alpha ligands and antitumor agents. Extensive analysis of structure-activity relationships for the 3-alkylidene chain revealed that polar groups such as ether, hydroxyl, aldehyde, ester, acyloxy, and amido were tolerated with similar binding affinities and reduced lipophilicities compared to the corresponding unsubstituted alkylidene chain. Among the derivatives, compounds 5, 6 and 8 with an ether type of side chain showed high binding affinities in range of K-i = 3-5 nM and excellent antitumor profiles, particularly against the colo205 colon cancer and the K562 leukemia cell lines. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.058

文献信息

• HIGH ENERGY RAY-CURABLE COMPOSITION
  申请人：Dow Corning Corporation

  公开号：EP1995260B1

  公开（公告）日：2016-07-20
• 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
  申请人：Genzyme Corporation

  公开号：US20180093981A1

  公开（公告）日：2018-04-05

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
• US9744153B2
  申请人：——

  公开号：US9744153B2

  公开（公告）日：2017-08-29
• US9745294B2
  申请人：——

  公开号：US9745294B2

  公开（公告）日：2017-08-29